Mechanism may explain aspects of brain impairment seen in Fragile X Syndrome

Scientists report that a protein associated with a common form of mental retardation plays an important role in intracellular trafficking within neurons. The research, published by Cell Press in the June issue of the journal Developmental Cell, reveals new information about how neuronal communication and plasticity are affected in Fragile X Syndrome (FXS).

FXS is a highly prevalent form of inherited mental impairment that also contributes to autism spectrum disorders. Most people with fragile X have a mutation that interferes with production of fragile X mental retardation protein (FMRP). FMRP binds to certain messenger RNAs (mRNAs), molecules that serve as chemical blueprints for production of proteins. Although FMRP targets mRNAs known to be critical for neuronal development and plasticity, exactly how FMRP influences these mRNAs was not well understood.

Neurons extend tendrils called "dendrites" outward from the main body of the cell so that they can communicate with other neuronal cells. These sites of communication, called "synapses", are important for learning and memory. Many neurons normally respond to stimuli, including synaptic signals from other neurons, by shunting certain key mRNAs to their dendrites. Study author Dr. Jason Dictenberg from City University of New York and colleagues, including Dr. Gary J. Bassell from Emory University, used high resolution fluorescence imaging methods in cultured neurons from embryonic mouse brain to explore how FMRP affects the intracellular localization of several target mRNAs in response to neuronal stimulation.

The researchers found that neurons lacking FMRP could not properly traffic mRNAs in response to stimuli. FMRP appeared to act as an adaptor for motor molecules involved in mRNA transport. Importantly, acute suppression of FMRP transport in normal neurons resulted in both diminished mRNA transport and a significant increase in the length and number of dendritic outgrowths called spine protrusions. This phenotype is similar to what is seen in the mouse model and in humans with FXS.

These results suggest that defects in stimulus-induced synaptic localization of FMRP target mRNAs may make a significant contribution to the synaptic and cognitive defects observed in FXS. "The present study has identified several key FMRP targets that are dysregulated in dendrites and may provide insight into new therapeutics for the treatment of FXS that target the mRNA localization pathway and its signaling components," concludes Dr. Bassell.

Source: Cell Press

Related stories:

Crucial progress in understanding Fragile X mental retardation protein
Researchers in the Department of Obstetrics, Gynecology & Reproductive Sciences at Yale School of Medicine have identified a new regulatory target for the Fragile X mental retardation protein (FMRP), laying the groundwork for possible new treatments for Fragile X syndrome(FXS), the leading inherited form of mental retardation.
Drosophila drug screen for fragile X syndrome finds promising compounds and potential drug targets
Scientists using a new drug screening method in Drosophila (fruit flies), have identified several drugs and small molecules that reverse the features of fragile X syndrome -- a frequent form of mental retardation and one of the leading known causes of autism. The discovery sets the stage for developing new treatments for fragile X syndrome.
Fragile X retardation syndrome corrected in mice
Researchers working with mice have significantly alleviated a wide range of abnormalities due to fragile X syndrome by altering only a single gene, countering the effects of the fragile X mutation. They said their achievement offers the potential for treatment of the disorder, the most common form of inherited mental retardation and a leading identified genetic cause of autism. There is currently no treatment or therapy for fragile X syndrome, whose symptoms include mental retardation, epilepsy, and abnormal body growth.
Scientists identify fundamental brain defect, probable drug target in fragile X syndrome
Scientists have discovered how the gene mutation responsible for fragile X syndrome--the most common inherited form of mental retardation--alters the way brain cells communicate. In neurons cultured from laboratory rats, the scientists also were able to reverse the effects of the mutation using a drug targeted to the specific site in an upstream pathway of the defect. The finding could lead to the development of human therapies for this previously untreatable condition.
Stem cell research produces a key discovery for Fragile X Syndrome
An important finding has been made by McMaster researchers about Fragile X Syndrome (FXS), a sex-linked genetic disorder that affects approximately one in 4,000 males and one in 6,000 females.

News discussion:

Medicine & Health news